{"title":"3-D structural approach on the Hansenula polymorpha-derived PEGylated interferon-α2a","authors":"F. Mueller","doi":"10.1016/S1594-5804(09)60009-7","DOIUrl":null,"url":null,"abstract":"<div><p>The majority of interferons available for therapeutic use are derived from the prokaryote <em>E. coli</em>. A new recombinant human interferon α2a (IFN-α2a; Reiferon®) has been derived from the yeast <em>Hansenula polymorpha</em> – a eukaryotic expression system. Safety and efficacy for this drug was tested in patients with chronic hepatitis C in Egypt. The unmodified yeast-derived IFN-α2a is the basis for a newly developed PEGylated IFN-α2a (Reiferon Retard®) which will be described in the following.</p></div>","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2009-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(09)60009-7","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive and Liver Disease Supplements","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1594580409600097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
The majority of interferons available for therapeutic use are derived from the prokaryote E. coli. A new recombinant human interferon α2a (IFN-α2a; Reiferon®) has been derived from the yeast Hansenula polymorpha – a eukaryotic expression system. Safety and efficacy for this drug was tested in patients with chronic hepatitis C in Egypt. The unmodified yeast-derived IFN-α2a is the basis for a newly developed PEGylated IFN-α2a (Reiferon Retard®) which will be described in the following.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
